共 43 条
Cost-effectiveness of positron emission tomography-CT in the evaluation of cancer of unknown primary of the head and neck
被引:9
作者:
Smith, Kristine A.
[1
]
Dort, Joseph C.
[1
]
Hall, Stephen F.
[2
]
Rudmik, Luke
[1
]
机构:
[1] Univ Calgary, Div Otolaryngol Head & Neck Surg, Dept Surg, Calgary, AB T2N 2T9, Canada
[2] Queens Univ, Queens Canc Res Inst, Div Canc Care & Epidemiol, Dept Otolaryngol Head & Neck Surg, Kingston, ON K7L 3N6, Canada
来源:
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
|
2015年
/
37卷
/
12期
关键词:
cost-effectiveness;
positron emission tomography-CT;
head and neck cancer;
squamous cell carcinoma;
unknown primary;
SQUAMOUS-CELL CARCINOMA;
LYMPH-NODE METASTASES;
COMPUTED TOMOGRAPHY;
PRIMARY TUMOR;
CONVENIENT APPROXIMATION;
DIAGNOSTIC EVALUATION;
LIFE EXPECTANCY;
PRIMARY SITE;
WORK-UP;
MANAGEMENT;
D O I:
10.1002/hed.23830
中图分类号:
R76 [耳鼻咽喉科学];
学科分类号:
100213 ;
摘要:
Background. Positron emission tomography (PET)-CT is a useful diagnostic adjunct for cancer unknown primary (CUP) of the head and neck; however, the increased cost has not been justified with an economic evaluation in this patient population. Methods. A decision tree analysis was performed from the perspective of the third party payer. Primary outcome was cost per life year gained ($/LYG). The 2 comparative groups were: (1) PET-CT followed by panendoscopy versus (2) panendoscopy alone. Results. The incremental cost-effectiveness ratios for N1, N2, and N3 CUP were $369.83/LYG, $329.43/LYG, and $4900.28/LYG, respectively. The sensitivity analysis demonstrated a 96.8%, 97.1%, and 60.1% certainty that PET-CT is cost-effective for CUP with N1, N2, and N3 disease, respectively. Conclusion. The use of PET-CT in patients with N1 and N2 CUP is the cost-effective choice. The cost-effectiveness in N3 CUP is questionable and should be used on an individual case basis. (C) 2014 Wiley Periodicals, Inc.
引用
收藏
页码:1781 / 1787
页数:7
相关论文